Work

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-164966

Authors: Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Institutions: Mayo Clinic, Yale Cancer Center, Yale University, Dana-Farber Cancer Institute, National Institutes of Health, National Cancer Institute, Moffitt Cancer Center, The Ohio State University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310108958

FWCI: 0.469

Cites:

Cited by: 4

Related to: 10